CLX2 Sep 2025 16:53
For those that didn’t gleam the blockbuster 2 x RNS news:
201 new SPV PLUS 301 ENDOMETRIOSIS new Canadian patent
Tony Hickson, Chief Business Officer of Cancer Research Horizons, commented: "Cancer Research Horizons is committed to bringing new drugs to market and supports the development of drugs at all stages, especially in areas of high unmet clinical need. Hormone therapies such as Enzalutamide and Abiraterone have transformed prostate cancer treatment, but most patients eventually become resistant to this form of therapy and there remains an unmet need for new drugs to overcome drug resistance. Val201 has a unique mechanism of action and can be positioned to address these resistant forms of cancer, as well as potentially earlier stages of the disease to mitigate the side effects seen under hormone ablation. We are pleased that ValiRx and Blue Ribbon Bio will continue with the development of a version of the therapy optimised for clinical impact."
WE UNDERSTAND FROM ME IN PARTNERING TALKS…
CLX ALSO IN TALKS!
Cytolytix has completed development and evaluation of its second-generation delivery platform and scheduled materials for evaluation in Screenin3D's UpScale3Dlab-on-a-chip platform including Inaphaea's Triple Negative Breast Cancer Patient Derived Cell models provided under the Evaluation and Commercial Use agreement announced on 3 February 2025. The evaluation will include assessment of the potential to activate the host immune system through immunogenic cell death.
ValiRx CEO and Cytolytix Director, Mark Eccleston, will be presenting Cytolytix oncolytic peptide program at the Charles River Biotech Symposium in Carlsbad (7 - 10 September 2025) and at the Oxford Global Discovery & Development US 2025 in San Diego (2 - 3 October 2025) following a series of presentations earlier in the year. These meetings represent excellent partnering opportunities as exemplified by the deal with Omios Bio which followed IO 360 in Boston in January 2025. ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company and further non-dilutive funding options with our academic partners.
Sign In
Follow the stocks
